Marvel Biosciences signs LOI with Novatech for MB — 204 Phase 1 trial in Australia
Marvel Biosciences signed a letter of intent with Novatech to run a Phase 1 clinical program for autism candidate MB-204. Trial planned in Australia, targeting first-in-human safety, tolerability, and pharmacokinetics; single ascending dose study expected to start in Q4 2026.